SLC11A2 and ischemia: Of note is the NFkB responsiveness of the 1B/DMT1 promoter during the early phase of neuronal ischemia through epigenetic regulation by acetylation at lysine 310 of NFkB/RelA; on the contrary, the abrogation of acetylation at lysine 310 of RelA determined the neuroprotection during OGD, with the down-regulation of both DMT1 protein and promoter transactivation, thus defining the pivotal role of the NFκB-dependent-1B/(−)IRE DMT1 isoform in the early phase of post-ischemic neurodegeneration, both in vitro and in vivo [9,11].